Short description
Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.
Description
Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows them to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes.
It is based in Rochester, New York.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Rochester, New York, United States, North America
Founded on
January 1, 1997
Exited on
August 9, 2018
Went public on
August 9, 2018
Stock symbol
VCNX
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Uh Ohhhh, Cannot Access, Cannot Access, Blurry Noaccess
Sign in for full access
Founders
Maurice Zauderer, Steven Cobourn